Stock comparison
Corcept Therapeutics
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CORT
Corcept Therapeutics
Market cap
$6.46B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
Corcept Therapeutics CORT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CORT | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 68D | 65C | CORT |
| Benjamin Graham | 86C | 64C | CORT |
| Philip Fisher | 64C | 48D | CORT |
| Peter Lynch | 32F | 25F | CORT |
| Joel Greenblatt | 47D | 76B | GMAB |
| Charlie Munger | 60C | 68C | GMAB |
| Terry Smith | 68C | 71C | GMAB |
Side-by-side metrics
| Metric | CORT | GMAB |
|---|---|---|
| Market cap | $6.46B | $16.5B |
| P/E (TTM) | 122.0x | 6.2x |
| EV/EBIT | 131.9x | 12.0x |
| ROIC (TTM) | -1.23% | 43.78% |
| Gross margin | 98.25% | 93.88% |
| Net margin | 6.23% | 18.23% |
| Revenue CAGR 5y | 20.1% | -18.45% |
| EPS CAGR 5y | -0.52% | -23.48% |
| Debt / Equity | 0.0x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CORT leads on
- Revenue CAGR 5y20.1%vs -18.45%+192%
- EPS CAGR 5y-0.52%vs -23.48%+98%
- Debt / Equity0.0xvs 0.1x+79%
GMAB leads on
- ROIC (TTM)43.78%vs -1.23%+103%
- P/E (TTM)6.2xvs 122.0x+95%
- EV/EBIT12.0xvs 131.9x+91%
- Net margin18.23%vs 6.23%+66%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.